Tech Digest

Rapamycin Use Comes out of the Closet

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

June 11, 2018

Dear Reader,

Rapa Nui, also known as Easter Island, is a smallish island over 2,100 miles away from the coast of Chile, the closest continental point. It is known mostly for the hundreds of Moai—giant stone statues placed around the island by Polynesian builders—though history will remember it as the source of rapamycin.

Found in the soil of the tropical island, the compound has already changed the way geroscientists think about medicine, but I think the rapamycin revolution is only beginning.


The story started in the 1960s when Canadian researchers traveled to the isolated outcrop in the Pacific Ocean to find out why inhabitants were free of tetanus, a frequently fatal bacterial disease typical in the tropics. Scientists in Montreal examined the soil samples and isolated an anti-fungal molecule created by Streptomyces hygroscopicus bacteria.

Initially, researchers focused on rapamycin as a potential drug for treating fungal infections. After they discovered its immunosuppressant properties, rapamycin was approved for the prevention of transplant rejection. Additional research proved that it also had anti-cancer effects, but the most important discovery had to do with aging.

Animals treated with low doses of the compound aged slower and experienced lower rates of disease. Naturally, this led to massive scientific interest and research, which verified that the test animals’ health and lifespans improved by about 20%, slightly more for females.

The discovery shook the foundations of medical science, which had always viewed aging as a natural and immutable process.

Another subsequent finding may even more important. Older animals given rapamycin experienced rejuvenation and nearly all the benefits exhibited by younger animals given the drug. For gerontologists, this was a world-changing revelation that hasn’t been fully processed yet.

How Does It Work?

While we don’t have the whole picture yet, it is generally accepted that rapamycin triggers the same genetic switches activated by calorie restriction (CR). We know that severe calorie restriction with optimal nutrition (CRON) reduces disease rates and probably extends lifespans. Unfortunately, CR is incredibly unpleasant, and only a handful of (probably masochistic) humans can voluntarily live with constant hunger.

Various strategies to replicate CRON’s benefits have emerged, including intermittent fasting (IF) and compounds that mimic the biological impacts of fasting. The two most promising over-the-counter compounds are nicotinamide riboside and oxaloacetate. The most promising form of fasting is Valter Longo’s fasting mimicking diet (FMD).

I’ve written about all these topics before and won’t repeat myself today. I will, however, answer a reader’s question regarding a Brazilian study suggesting that IF may be harmful. In fact, the study didn’t address intermittent fasting. It tested a weird variant on rats that were fed only every other day.

There are many reasons we shouldn’t extrapolate that study to humans, the most obvious being that to an animal with a rat’s rapid metabolism, a day compares to weeks in human time. Regardless, I wouldn’t recommend an every-other-day IF for humans because it doesn’t approximate the cycles of famine and feast that our ancestors adapted to. Most people who do some form of IF simply limit eating to part of the day or refrain one or two days a week, which is not associated with health risks.


Longo’s FMD makes the most sense because five consecutive days of low caloric intake mimics the periods of seasonal hunger that most humans experienced in the past. There is increasing evidence that our species needs cycles of hunger and plenty to slow aging. In fact, Longo has shown that FMD impacts the mTOR (mechanistic target of rapamycin) pathways that are associated with longer healthspans.

With so much evidence regarding rapamycin’s positive impacts on health and lifespan, you’re probably asking a simple question: Why aren’t we all taking it?

The answer is more complicated than you might assume.

What Science “Knows” Gets in the Way

Rapamycin affects both the mTORC1 (mTOR Complex 1) and mTORC2 (mTOR Complex 2) pathways. Suppressing mTORC1 produces health benefits while blocking mTORC2 over the long term causes side effects—notably mouth sores and symptoms of type-2 diabetes.

That’s why I’ve covered several companies working on new forms of rapamycin, known as rapalogs, that have less mTORC2 impact. These drugs would presumably be safer and could be taken through the clinical-trial process for various diseases.

While this is true, it ignores some basic facts. The biggest is that in animal trials, rapamycin has delivered significant health benefits without the side effects.

How is that possible?

The answer, of course, is dose.

Animals receive low doses, unlike those taken by patients who need to prevent transplant rejection. All known drugs have different effects based on dosage—so it makes sense that lower doses of rapamycin means lower risks. Nevertheless, some scientists simply assume that generic rapamycin, known as sirolimus or rapamune, is unsuitable or at least inferior to future hypothetical rapalogs.

Honestly, we don’t know if that’s true. There’s no profit in paying tens of millions to take a generic drug through clinical trials, which would settle the question. Even if current manufacturers cooperated to prove that rapamycin is a breakthrough anti-aging drug, it’s unlikely they would ever recoup the costs of the trial. If a market for rapamycin were created, new manufacturers of the generic version would manufacture the drug.

Currently, we’re seeing efforts to take metformin, also a generic drug, through the trial process, but it has proven extremely difficult to raise the enormous sums needed to satisfy the FDA’s clinical requirements. Until an anti-aging trial is completed, there will be no regulatory roadmap for those who want to develop marketable drugs for aging.

At some point in the future, rapalogs may undergo clinical trials for various age-related diseases, but they will have to be used off-label for anti-aging purposes. That means they probably won’t be covered by insurance and will be more expensive than the generic form of rapamycin that is currently available.

Dogs First, Humans Next?


This is enormously frustrating, but it is the reality of our healthcare system. For years, I’ve heard whispers that scientists and researchers are using low-dose rapamycin for anti-aging purposes. I’ve also heard rumors that some are dosing their pets to keep them alive and healthy longer. In fact, the University of Washington’s Dog Aging Project is putting together a network of clinicians and scientists to carry out rapamycin research in pets.

I’ve spoken with a number of well-known geroscientists about the Dog Aging Project. They all support it and believe it will help create public support for anti-aging medicine. Animal trials are less expensive than human trials, but they will still take years to complete.

If we all play by the rules, we can expect to see rapamycin trials in dogs, which would take at least three to five years. They would be followed by human trials of a rapalogs that would probably take as long.

Of course, the problem is that a lot of people don’t have that much time. If we wait until the government approves the drug for aging, a lot of people who could have been rejuvenated by rapamycin will have died.

Ironically, rapamycin therapy is legal, though not approved. This is because the FDA allows drugs approved for any indication to be used “off-label” for other uses. In fact, many drugs are used more for off-label than approved uses, and the practice is recognized by the FDA.

Though off-label rapamycin use has been going on for some time, few people have been willing to talk about it. Generally, the users have been scientists, doctors, and veterinarians who could extrapolate animal trials to determine optimal human dosages. Patients who lacked expertise and a medical license were out of luck.

That seems to be changing. Right after Congress passed the Right to Try legislation to help dying patients get access to experimental drugs, a reader contacted me to say that he’s started rapamycin therapy through a doctor in New York.  

Doctors Swimming Against the Stream

I spoke at length with that physician, Alan Green, M.D., and was impressed by his knowledge and motives. Doctor Green retired from his medical practice while in his sixties but started to research aging when he began to lose strength and stamina in his seventies.

He focused on rapamycin and studied its pharmacokinetics and dosing. Eventually, he began taking the drug himself and reports the same sort of rejuvenation we’ve seen in animal studies. His health improved to such an extent, he decided to reopen his practice so that he could help others familiar with the science of rapamycin get access to the supervised therapy.

Green now has more than 90 patients who have tracked him down through his website, which contains a plethora of critical information about rapamycin. His office is in Little Neck, New York, and state law requires that he personally see patients before he can write prescriptions for them. Some of his patients have traveled from New Zealand, Sweden, and Canada for appointments.

Green is clearly not in it for the money. He charges a typical consultation fee, which he describes as expensive because it’s not covered by insurance. He prescribes generic rapamycin, which is relatively inexpensive at Walmart with the use of a GoodRx coupon. On a monthly basis, the cost of therapy ranges from about $60 to $150 depending on the patient’s age, weight, and medical condition. 

Green reports no serious side effects at low doses comparable to those used in animal studies, meaning 3–6 mg per week. He told me the exception was patients who drank a lot of grapefruit juice, which is known to slow metabolism of rapamycin. The key to proper dosing, Green says, is to give enough of the drug in a period to affect mTORC1 without provoking increased mTORC2 activity. Many of the papers he has used to design his therapies are on his website.

I think Dr. Green’s rapidly growing business is an indicator of changing attitudes, helped along by the media’s increasing interest in rapamycin. A good example is this CNN story published last year: “This pill could make your dog (and maybe you) live longer.”

Green is only one doctor, and most people outside of New York City won’t be able to see him. However, I think he represents a trend. I wrote about him a few weeks ago in my financial newsletter and a few days later got a call from a doctor friend here in Florida. He studied Green’s website and was so impressed that he’s thinking about switching his medical practice to rapamycin and anti-aging therapies.

I talked with him about even more effective healthspan extension therapies that will be coming to market in the next years. The dilemma, of course, is that a lot of people won’t live long enough to take advantage of more effective therapies unless they slow aging now. My friend wants to help people live longer, with lower healthcare costs, in the meantime.

I’m not a doctor, of course, so you shouldn’t take or avoid rapamycin based on my opinions. Even when taking drugs for specifically approved purposes, my attitude is: Caveat mTOR.

Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics


Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest

Your privacy is very important to us. Please review our Privacy Policy.


« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This


We welcome your comments. Please comply with our Community Rules.


Walt Spaude

June 12, 12:40 p.m.

Great article,

Just wondering if anyone at Mauldin Economics takes Rapamycin and/or Metformin and at what doses. If so, what is the consensus to date? Immediate perceived health benefits or hoped for greater long-term health and longevity?


Carl Pfeiffer

June 11, 9:37 p.m.

I did the forty day fast many years ago on a whim as an experiment without any guide or instructions.  I learned from that experience how little food I need to live healthy, enjoy great health, and oddly, that the less I eat the more energy I have.  The opposite, when I eat more, like three a day, I feel bloated, lethargic and tired.  Not a big fan of cruises with all that great tempting food, too easy to fall off the wagon.

One of the biggest problems in our culture as I see it, is the way we eat.  Many typically skimp or pass on breakfast, lunch of some size, and then feast out at dinner.  The reverse is actually the best way due to our natural metabolism rate - breakfast like a king, lunch like a prince, and dinner like a pauper.

The Longo diet plan which I only glossed over, and have unknowingly followed for years works for me.  And yes, reckon I’m one of those masochistic types that lives hungry most of the time.  Works for me….!!  Every physical in the past ten plus years I get a perfect patient comment from my doc.  Even though he wants me to quit smoking, I eat whatever I want and don’t work out regularly, I can outwork just about anyone.  Go figure…..LOL

I have always binged on saturated fats, but avoid polyunsaturated fats (the bad guys actually) like the plague, and almost all soy products.  Reminds me of the Oldtimer’s cartoon about the older generation - Essential Oil = Bacon Grease (& lard).  Odd how cardio-cholesterol problems didn’t really appear in medical books till poly-unsaturated fats were introduced into our diets in the twenties.

Michael Price 10136073

June 11, 2:30 p.m.

Patrick, can you provide contact information for the doctor in Florida that is considering shifting his practice to focus on rapamycin and other anti-aging therapies?

Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact


The Mauldin Economics website, Thoughts from the Frontline, The Weekly Profit, The 10th Man, Connecting the Dots, Transformational Technology Digest, Over My Shoulder, Yield Shark, Transformational Technology Alert, Rational Bear, Street Freak, ETF 20/20, In the Money, and Mauldin Economics VIP are published by Mauldin Economics, LLC Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics